Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease.

Björkqvist M, Ohlsson M, Minthon L, Hansson O.

PLoS One. 2012;7(1):e29868. doi: 10.1371/journal.pone.0029868. Epub 2012 Jan 18.

3.

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease.

Silajdžić E, Björkqvist M, Hansson O.

BMC Neurol. 2015 Feb 5;15:8. doi: 10.1186/s12883-015-0260-1.

4.

Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease.

Menendez-Gonzalez M, Castro-Santos P, Suarez A, Calatayud MT, Perez-Pinera P, Martinez M, Ribacoba R, Gutierrez C.

J Alzheimers Dis. 2008 May;14(1):59-67.

PMID:
18525128
6.

Blood-based protein biomarkers for diagnosis of Alzheimer disease.

Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group.

Arch Neurol. 2012 Oct;69(10):1318-25.

PMID:
22801742
7.

No diagnostic value of plasma clusterin in Alzheimer's disease.

Silajdžić E, Minthon L, Björkqvist M, Hansson O.

PLoS One. 2012;7(11):e50237. doi: 10.1371/journal.pone.0050237. Epub 2012 Nov 28.

8.

A candidate plasma protein classifier to identify Alzheimer's disease.

Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj TC, Holder DJ, Dai H, Weiner R, Laterza OF.

J Alzheimers Dis. 2015;43(2):549-63. doi: 10.3233/JAD-141149.

PMID:
25114072
9.
10.

Role of Plasma Clusterin in Alzheimer's Disease-A Pilot Study in a Tertiary Hospital in Northern India.

Vishnu VY, Modi M, Sharma S, Mohanty M, Goyal MK, Lal V, Khandelwal N, Mittal BR, Prabhakar S.

PLoS One. 2016 Nov 18;11(11):e0166369. doi: 10.1371/journal.pone.0166369. eCollection 2016.

11.

Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project.

Arch Neurol. 2012 Oct;69(10):1310-7.

12.

A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.

Olazarán J, Gil-de-Gómez L, Rodríguez-Martín A, Valentí-Soler M, Frades-Payo B, Marín-Muñoz J, Antúnez C, Frank-García A, Acedo-Jiménez C, Morlán-Gracia L, Petidier-Torregrossa R, Guisasola MC, Bermejo-Pareja F, Sánchez-Ferro Á, Pérez-Martínez DA, Manzano-Palomo S, Farquhar R, Rábano A, Calero M.

J Alzheimers Dis. 2015;45(4):1157-73. doi: 10.3233/JAD-142925.

PMID:
25649659
14.

Measurement of Blood Thiamine Metabolites for Alzheimer's Disease Diagnosis.

Pan X, Fei G, Lu J, Jin L, Pan S, Chen Z, Wang C, Sang S, Liu H, Hu W, Zhang H, Wang H, Wang Z, Tan Q, Qin Y, Zhang Q, Xie X, Ji Y, Cui D, Gu X, Xu J, Yu Y, Zhong C.

EBioMedicine. 2015 Nov 26;3:155-162. doi: 10.1016/j.ebiom.2015.11.039. eCollection 2016 Jan.

15.

Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.

Hansson O, Stomrud E, Vanmechelen E, Östling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I.

J Alzheimers Dis. 2012;28(1):231-8. doi: 10.3233/JAD-2011-111418.

PMID:
21955816
16.

Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.

Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, Lee DH, Ye BS, Kim JH, Kim EJ, Park KH, Han HJ, Jeong JH, Choi SH, Park SA.

J Alzheimers Dis. 2015;48(4):1043-50. doi: 10.3233/JAD-143018.

PMID:
26444752
17.

Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.

Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus Ch, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J.

Exp Neurol. 2010 Jun;223(2):366-70. doi: 10.1016/j.expneurol.2009.07.024. Epub 2009 Aug 5.

PMID:
19664622
18.

Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues.

O'Bryant SE, Xiao G, Zhang F, Edwards M, German DC, Yin X, Como T, Reisch J, Huebinger RM, Graff-Radford N, Dickson D, Barber R, Hall J, O'Suilleabhain P, Grammas P.

J Alzheimers Dis. 2014;42(4):1325-35. doi: 10.3233/JAD-141041.

19.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
20.

Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Prasher VP, Sajith SG, Mehta P, Zigman WB, Schupf N.

Int J Geriatr Psychiatry. 2010 Feb;25(2):202-7. doi: 10.1002/gps.2321.

Supplemental Content

Support Center